A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

Eligibility Criteria

• 1. Signed the informed consent form before any study-related procedure.
• 2. All females must have a negative serum pregnancy test at the Screening Visit and on admission to the Clinical Unit
• 3. Females of non-childbearing potential must be confirmed at the Screening Visit by fulfilling one of the following criteria: postmenopausal or surgically sterilized females.
• 4. Have a Body Mass Index (BMI) \> 18 kg/m² and weigh at least 50 kg.
• 5. Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods.
• 6. Fasting LDL-C \> 100 mg/dL but \< 190 mg/dL (\> 2.6 mmol/L but \< 4.9 mmol/L for London EPCU) at the Screening Visit.
• 7. Fasting triglycerides \< 400 mg/dL (or \< 10.3 mmol/L for London EPCU) at the Screening Visit.
• 1. History of any clinically important disease or disorder.
• 2. History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• 3. Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
• 4. Any laboratory values with specific deviations in alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin (TBL), estimated glomerular filtration rate, or hemoglobin at the Screening Visit or on Admission
• 5. Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results other than those described under exclusion criterion number 4, at Screening and/or Admission to the Clinical Unit
• 6. Any positive result on Screening for serum HBsAg, hepatitis B core antibody or human immunodeficiency virus.
• 7. History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD0780, ezetimibe, rosuvastatin, and bempedoic acid.
• 8. Treatment with any lipid-lowering therapy or AZD0780 within the 3 months prior to Screening.
• 9. Treatment with drugs for reduction or inhibition of Proprotein convertase subtilisin/kexin type 9 (PCSK9) within the last 12 months prior to Screening (approved or investigational and apart from AZD0780).